Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Virpax Pharmaceuticals, Inc.: Amended certificate of incorporation to effect a 1-for-10 reverse stock split (effective 2024-03-01).
- Change
- charter amendment
- Effective
- 2024-03-01
Exact text from the filing
on February 29, 2024, the Company filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the "Amendment") with the Secretary of State of the State of Delaware to effect the reverse stock split, with an effective time (the "Effective Time") of 12:01 a.m. Eastern Time on March 1, 2024
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Virpax Pharmaceuticals, Inc. entered into Settlement Agreement and Mutual Release with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. valued at $6 million (effective 2024-02-29).
- Action
- entry
- Agreement
- settlement
- Counterparty
- Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc.
- Value
- $6 million
- Effective
- 2024-02-29
Exact text from the filing
On February 29, 2024, Virpax Pharmaceuticals, Inc. ( the “Company”) and Sorrento Therapeutics, Inc. (“Sorrento”) and Scilex Pharmaceuticals Inc. (“Scilex”) executed a Settlement Agreement and Mutual Release (the “Agreement”) to fully resolve all issues related to the litigation between the Company (a defendant) and Sorrento and Scilex (collectively, referred to as the “Plaintiffs”) captioned Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. v. Anthony Mack and Virpax Pharmaceuticals, Inc ., Case No. 2021-0210-PAF (the “Action”), all subject to the entry by the United States Bankruptcy Court for the Southern District of Texas, which is handling the Sorrento bankruptcy filing (the “Bankruptcy Court”), of an order approving the Agreement (the “Settlement Order”).
View on SEC.gov